Antibody Drug Conjugates for HER2DX Negative Metastatic Disease

Tres2sumab deruxticon or TDXD and sasatuzumabgovatikan. We have now two drugs that are approved in the pre-treated setting so for clearly you should be endocrine resistant. The best treatment for these patients upfront is endocrine based but when you start to get to the chemotherapy the tools we have now include these antibody drug conjugates. It's actually a really exciting time because you know most patients end up getting chemotherapy at some point.